scPharmaceuticals (NASDAQ:SCPH) Price Target Lowered to $12.00 at Craig Hallum

scPharmaceuticals (NASDAQ:SCPH) had its price objective reduced by Craig Hallum from $16.00 to $12.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Trading Down 8.0 %

Shares of SCPH stock traded down $0.27 during trading hours on Thursday, hitting $3.09. 658,346 shares of the company were exchanged, compared to its average volume of 266,770. The company has a 50 day simple moving average of $4.53 and a two-hundred day simple moving average of $4.50. The firm has a market cap of $154.59 million, a P/E ratio of -1.63 and a beta of 0.15. The company has a debt-to-equity ratio of 4.32, a quick ratio of 3.66 and a current ratio of 4.84. scPharmaceuticals has a fifty-two week low of $3.08 and a fifty-two week high of $6.71.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $8.05 million during the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 263.11%. Equities analysts anticipate that scPharmaceuticals will post -1.34 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Captrust Financial Advisors raised its stake in shares of scPharmaceuticals by 32.2% during the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock worth $85,000 after purchasing an additional 4,513 shares during the period. Walleye Capital LLC raised its position in scPharmaceuticals by 27.0% in the third quarter. Walleye Capital LLC now owns 475,555 shares of the company’s stock worth $2,169,000 after acquiring an additional 101,148 shares during the period. Suvretta Capital Management LLC bought a new stake in scPharmaceuticals in the third quarter worth about $9,343,000. Stonepine Capital Management LLC boosted its stake in scPharmaceuticals by 84.7% in the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after acquiring an additional 357,171 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of scPharmaceuticals by 135.0% during the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock worth $77,000 after purchasing an additional 9,752 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.